<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513717</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-GU009</org_study_id>
    <secondary_id>NCI-2020-04705</secondary_id>
    <secondary_id>NRG-GU009</secondary_id>
    <secondary_id>NRG-GU009</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT04513717</nct_id>
  </id_info>
  <brief_title>Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial</brief_title>
  <official_title>Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares less intense hormone therapy and radiation therapy to usual&#xD;
      hormone therapy and radiation therapy in treating patients with high risk prostate cancer and&#xD;
      low gene risk score. This trial also compares more intense hormone therapy and radiation&#xD;
      therapy to usual hormone therapy and radiation therapy in patients with high risk prostate&#xD;
      cancer and high gene risk score. Abiraterone acetate may help fight prostate cancer by&#xD;
      lowering the amount of testosterone made by the body. Apalutamide may help fight prostate&#xD;
      cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy&#xD;
      rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may&#xD;
      work the same at controlling prostate cancer compared to the usual 24 month hormone therapy&#xD;
      treatment in patients with low gene risk score. Adding abiraterone acetate and apalutamide to&#xD;
      the usual treatment may increase the length of time without prostate cancer spreading as&#xD;
      compared to the usual treatment in patients with high gene risk score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether men with National Comprehensive Cancer Network (NCCN) high risk&#xD;
      prostate cancer who are in the lower 2/3 of Decipher genomic risk (=&lt; 0.8) can be treated&#xD;
      with 12 months androgen deprivation therapy (ADT) plus radiation therapy (RT) instead of 24&#xD;
      months ADT+RT and experience non-inferior metastasis-free survival. (De-intensification&#xD;
      study) II. To determine whether men with NCCN high risk prostate cancer who are in the upper&#xD;
      1/3 of Decipher genomic risk (&gt; 0.8) or have node-positive disease by conventional imaging&#xD;
      (magnetic resonance imaging [MRI] or computed tomography [CT] scan) will have a superior&#xD;
      metastasis-free survival (MFS) through treatment intensification with apalutamide and&#xD;
      abiraterone acetate with prednisone added to the standard of RT plus 24 month ADT.&#xD;
      (Intensification study)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare overall survival (OS) between the standard of care (RT plus 24 months of ADT)&#xD;
      and either the de intensification (RT plus 12 months of ADT) or intensification arm (RT plus&#xD;
      24 months of ADT plus apalutamide and abiraterone acetate with prednisone).&#xD;
      (De-intensification and intensification studies) II. To compare time to prostate specific&#xD;
      antigen (PSA) failure or start of salvage treatment between the standard of care (RT plus 24&#xD;
      months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or&#xD;
      intensification arm (RT plus 24 months of ADT plus apalutamide and abiraterone acetate with&#xD;
      prednisone). (De-intensification and intensification studies) III. To compare PSA&#xD;
      failure-free survival with non-castrate testosterone and no additional therapies between the&#xD;
      standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12&#xD;
      months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide and&#xD;
      abiraterone acetate with prednisone). (De-intensification and intensification studies) IV. To&#xD;
      compare MFS judged based on either standard or molecular imaging between the standard of care&#xD;
      (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT)&#xD;
      or intensification arm (RT plus 24 months of ADT plus apalutamide and abiraterone acetate&#xD;
      with prednisone). (De-intensification and intensification studies) V. To compare prostate&#xD;
      cancer-specific mortality between the standard of care (RT plus 24 months of ADT) and either&#xD;
      the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24&#xD;
      months of ADT plus apalutamide and abiraterone acetate with prednisone). (De-intensification&#xD;
      and intensification studies) VI. To compare testosterone levels at the time of PSA failure&#xD;
      and metastases between the standard of care (RT plus 24 months of ADT) and either the&#xD;
      de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months&#xD;
      of ADT plus apalutamide and abiraterone acetate with prednisone). (De-intensification and&#xD;
      intensification studies) VII. To compare time to testosterone recovery (defined as a T &gt; 200)&#xD;
      between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm&#xD;
      (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide&#xD;
      and abiraterone acetate with prednisone). (De-intensification and intensification studies)&#xD;
      VIII. To compare adverse events, both clinician-reported using Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) version (v) 5.0 and patient-reported using patient reported&#xD;
      outcome (PRO)-CTCAE items, between the standard of care (RT plus 24 months of ADT) and either&#xD;
      the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24&#xD;
      months of ADT plus apalutamide and abiraterone acetate with prednisone). (De-intensification&#xD;
      and intensification studies)&#xD;
&#xD;
      CORRELATIVE STUDIES OBJECTIVE:&#xD;
&#xD;
      I. To compare extra-prostatic uptake on the positron emission tomography (PET)-CT between the&#xD;
      standard of care (RT plus 24 months of ADT) and intensification arm (RT plus 24 months of ADT&#xD;
      plus apalutamide and abiraterone acetate with prednisone). (Intensification study)&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To compare changes in cardio-metabolic markers, including body mass index, and waist&#xD;
      circumference, between the standard of care (RT plus 24 months of ADT) and either the&#xD;
      de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months&#xD;
      of ADT plus apalutamide and abiraterone acetate with prednisone). (De-intensification and&#xD;
      intensification studies) II. To determine a machine learning/artificial intelligence&#xD;
      algorithm for radiotherapy quality assurance. (De-intensification and Intensification&#xD;
      studies) III. To perform future translational correlative studies using biological and&#xD;
      imaging data. (De-intensification and intensification studies)&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 4 arms.&#xD;
&#xD;
      DE-INTENSIFICATION STUDY (DECIPHER SCORE =&lt; 0.8):&#xD;
&#xD;
      ARM I: Patients undergo radiation therapy (RT) over 4-9 weeks and receive ADT (consisting of&#xD;
      either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide&#xD;
      or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide,&#xD;
      goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for&#xD;
      12 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      INTENSIFICATION STUDY (DECIPHER SCORE &gt; 0.8 OR NODE POSITIVE):&#xD;
&#xD;
      ARM III: Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide,&#xD;
      goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for&#xD;
      24 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM IV: Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide,&#xD;
      goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients also receive apalutamide, abiraterone&#xD;
      acetate and prednisone orally (PO) once daily (QD). Treatment repeats every 90 days for up to&#xD;
      8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Design change&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2038</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2033</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-Free Survival (MFS)</measure>
    <time_frame>From randomization to the date of detection of distant metastasis on standard imaging or date of death from any cause, assessed up to 13 years</time_frame>
    <description>Assessed based on conventional imaging. MFS will be estimated using the Kaplan-Meier method (Kaplan 1958).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to the date of death or last known follow-up date, with patients alive at the last known follow-up time treated as censored, assessed up to 13 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test (Kaplan 1958).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) failure-free survival with non-castrate testosterone and no additional therapies</measure>
    <time_frame>From the date of randomization to the date event, or death or censored at the last known follow-up date, assessed up to 13 years</time_frame>
    <description>PSA failure-free survival will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test (Kaplan 1958).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer Specific Mortality (PCSM)</measure>
    <time_frame>From the date of randomization to the date of prostate cancer death, assessed up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to testosterone recovery</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as testosterone that is non-castrate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA failure or salvage therapy</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone levels at the time of PSA failure and metastases</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Measured by the Common Terminology Criteria for Adverse Events (CTCAE ) version (v) 5.0 and Patient Reported Outcomes (PRO)-CTCAE.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2478</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Bone</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage III Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <condition>Stage IVA Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo RT over 4-9 weeks and receive ADT as in Arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiation therapy over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide, abiraterone acetate and prednisone PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Yonsa</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>Erleada</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Hormone therapy. Given PO</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <other_name>Casodex</other_name>
    <other_name>Cosudex</other_name>
    <other_name>ICI 176,334</other_name>
    <other_name>ICI 176334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buserelin</intervention_name>
    <description>Hormone therapy. Given by injection.</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)</other_name>
    <other_name>BSRL</other_name>
    <other_name>Busereline</other_name>
    <other_name>Etilamide</other_name>
    <other_name>HOE 766</other_name>
    <other_name>ICI 123215</other_name>
    <other_name>S74-6766</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Hormone therapy. Given by injection.</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <other_name>4''-Nitro-3''-trifluoromethylisobutyranilide</other_name>
    <other_name>Apimid</other_name>
    <other_name>Cebatrol</other_name>
    <other_name>Chimax</other_name>
    <other_name>Cytomid</other_name>
    <other_name>Drogenil</other_name>
    <other_name>Euflex</other_name>
    <other_name>Eulexine</other_name>
    <other_name>Flucinom</other_name>
    <other_name>Flucinome</other_name>
    <other_name>Flugerel</other_name>
    <other_name>Fluken</other_name>
    <other_name>Flulem</other_name>
    <other_name>FLUT</other_name>
    <other_name>Fluta-Gry</other_name>
    <other_name>Flutabene</other_name>
    <other_name>Flutacan</other_name>
    <other_name>Flutamex</other_name>
    <other_name>Flutamin</other_name>
    <other_name>Flutan</other_name>
    <other_name>Flutaplex</other_name>
    <other_name>Fugerel</other_name>
    <other_name>Grisetin</other_name>
    <other_name>Niftolide</other_name>
    <other_name>Oncosal</other_name>
    <other_name>Profamid</other_name>
    <other_name>Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-</other_name>
    <other_name>Prostacur</other_name>
    <other_name>Prostadirex</other_name>
    <other_name>Prostica</other_name>
    <other_name>Prostogenat</other_name>
    <other_name>Sch 13521</other_name>
    <other_name>Tafenil</other_name>
    <other_name>Tecnoflut</other_name>
    <other_name>Testotard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>ICI-118630</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histrelin</intervention_name>
    <description>Anti-gonadotropin</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Hormone therapy.</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>Leuprorelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>RT + ADT for 12 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (De-Intensification)</arm_group_label>
    <arm_group_label>RT + ADT for 24 months (Intensification)</arm_group_label>
    <arm_group_label>RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)</arm_group_label>
    <other_name>6-D-Tryptophan-LH-RH</other_name>
    <other_name>6-D-Tryptophanluteinizing Hormone-releasing Factor</other_name>
    <other_name>AY-25650</other_name>
    <other_name>CL-118,532</other_name>
    <other_name>Detryptoreline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PRIOR TO STEP 1 REGISTRATION&#xD;
&#xD;
          -  Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days&#xD;
             prior to registration&#xD;
&#xD;
          -  High-risk disease defined as having at least one or more of the following:&#xD;
&#xD;
               -  PSA &gt; 20 ng/mL prior to starting ADT&#xD;
&#xD;
               -  cT3a-T4 by digital exam or imaging (American Joint Committee on Cancer [AJCC] 8th&#xD;
                  edition [Ed.])&#xD;
&#xD;
               -  Gleason score of 8-10&#xD;
&#xD;
               -  Node positive by conventional imaging with a short axis of at least 1.0 cm&#xD;
&#xD;
          -  Appropriate stage for study entry based on the following diagnostic workup:&#xD;
&#xD;
               -  History/physical examination within 120 days prior to registration;&#xD;
&#xD;
               -  Bone imaging within 120 days prior to registration;&#xD;
&#xD;
                    -  Note: To be eligible, patient must have no definitive evidence of bone&#xD;
                       metastases (M0) on bone scan or sodium fluoride (NaF) PET within 120 days&#xD;
                       prior to registration (negative Na F PET/CT or negative axumin or choline&#xD;
                       PET or negative fluciclovine, choline or prostate-specific membrane antigen&#xD;
                       (PSMA) PET within 120 days prior to registration is an acceptable substitute&#xD;
                       if they have been performed). Patients who have bone metastases established&#xD;
                       only fluciclovine, choline, or PSMA PET but not definitive on bone scan or&#xD;
                       Na F PET will still be eligible&#xD;
&#xD;
               -  CT or MRI of the pelvis within 120 days prior to registration (negative&#xD;
                  fluciclovine, choline, or PSMA PET within 120 days prior to registration is an&#xD;
                  acceptable substitute). As with bone staging, nodal staging for trial purposes&#xD;
                  will be based off of conventional imaging findings only&#xD;
&#xD;
               -  Patients with confirmed N1 metastases on conventional imaging (CT/MRI) as defined&#xD;
                  by &gt; 10 mm on short axis are eligible but will be automatically assigned to the&#xD;
                  intensification study. Patients who are positive by fluciclovine, choline, or&#xD;
                  PSMA PET (i.e. N1), but whose nodes do not meet traditional size criteria for&#xD;
                  positivity (i.e. they measure =&lt; 10 mm on either the CT or MRI portion of the PET&#xD;
                  or on a dedicated CT or MRI) will not be considered N1 for the trial and will not&#xD;
                  automatically be assigned to the intensification study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL, independent of transfusion and/or growth factors (within 120&#xD;
             days prior to registration)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 x 10^9/uL independent of transfusion and/or growth factors&#xD;
             (within 120 days prior to registration)&#xD;
&#xD;
          -  Creatinine clearance (CrCl) &gt;= 30 mL/min estimated by Cockcroft-Gault equation (within&#xD;
             120 days prior to registration)&#xD;
&#xD;
               -  For Black patients whose renal function is not considered adequate by&#xD;
                  Cockcroft-Gault formula, an alternative formula that takes race into account&#xD;
                  (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) may be used&#xD;
                  for calculating creatinine clearance for trial eligibility&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) within 120 days&#xD;
             prior to registration&#xD;
&#xD;
               -  Note: In subjects with Gilbert's syndrome, if total bilirubin is &gt; 1.5 x ULN,&#xD;
                  measure direct and indirect bilirubin and if direct bilirubin is =&lt; 1.5 x ULN,&#xD;
                  subject is eligible&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) or&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             institutional ULN (within 120 days prior to registration)&#xD;
&#xD;
          -  Serum albumin &gt;= 3.0 g/dL (within 120 days prior to registration)&#xD;
&#xD;
          -  The patient must agree to use a condom (even men with vasectomies) and another&#xD;
             effective method of birth control if he is having sex with a woman of childbearing&#xD;
             potential or agree to use a condom if he is having sex with a woman who is pregnant&#xD;
             while on study drug and for 3 months following the last dose of study drug&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral&#xD;
             therapy (didanosine [DDI] is not permitted) with undetectable viral load within 6&#xD;
             months are eligible for this trial and have a CD4 count &gt;= 200 cells/microliter within&#xD;
             60 days prior to registration. Note: HIV testing is not required for eligibility for&#xD;
             this protocol. Of note, for patients with HIV in the intensification trial randomized&#xD;
             to abiraterone acetate and apalutamide, highly active antiretroviral therapy (HAART)&#xD;
             may need to be adjusted to medications that do not interact with abiraterone acetate&#xD;
             and apalutamide&#xD;
&#xD;
          -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral&#xD;
             load must be undetectable after or on suppressive therapy within 60 days prior to&#xD;
             registration, if indicated. Note: HBV viral testing is not required for eligibility&#xD;
             for this protocol&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial. Note: Any patient with a cancer&#xD;
             (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle&#xD;
             invasive bladder cancer) who has been disease-free for less than 3 years must contact&#xD;
             the principal investigator&#xD;
&#xD;
          -  The patient or a legally authorized representative must provide study-specific&#xD;
             informed consent prior to study entry&#xD;
&#xD;
          -  PRIOR TO STEP 2 RANDOMIZATION&#xD;
&#xD;
          -  Confirmation of Decipher score&#xD;
&#xD;
          -  Patients with a history of hepatitis C virus (HCV) infection must have been treated&#xD;
             and cured. For patients with HCV infection who are currently on treatment, they are&#xD;
             eligible if they have an undetectable HCV viral load within 60 days prior. Note:&#xD;
             Apalutamide may interfere with HCV drugs. Patients on HCV medications should alert&#xD;
             their infectious diseases physician if they get randomized to apalutamide due to the&#xD;
             possibility that apalutamide can affect the bioavailability of some HCV medications.&#xD;
             HCV viral testing is not required for eligibility for this protocol&#xD;
&#xD;
          -  For patients entering the Intensification Cohort ONLY: Patients must discontinue or&#xD;
             substitute concomitant medications known to lower the seizure threshold at least 30&#xD;
             days prior to Step 2 randomization&#xD;
&#xD;
          -  For patients entering the Intensification Cohort ONLY: Serum potassium &gt;= 3.5 mmol/L&#xD;
             prior to Step 2 randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PRIOR TO STEP 1 REGISTRATION:&#xD;
&#xD;
          -  Definitive radiologic evidence of metastatic disease outside of the pelvic nodes (M1a,&#xD;
             M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI)&#xD;
&#xD;
          -  Prior systemic chemotherapy within =&lt; 3 years prior to registration; note that prior&#xD;
             chemotherapy for a different cancer is allowed (completed &gt; 3 years prior to&#xD;
             registration&#xD;
&#xD;
          -  Prior radical prostatectomy&#xD;
&#xD;
          -  Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields&#xD;
&#xD;
          -  Current use of 5-alpha reductase inhibitor. NOTE: If the alpha reductase inhibitor is&#xD;
             stopped prior to randomization the patient is eligible&#xD;
&#xD;
          -  Didanosine (DDI) antiretroviral therapy is not permitted&#xD;
&#xD;
          -  History of any of the following:&#xD;
&#xD;
               -  Seizure disorder&#xD;
&#xD;
               -  Current severe or unstable angina&#xD;
&#xD;
               -  New York Heart Association Functional Classification III/IV (Note: Patients with&#xD;
                  known history or current symptoms of cardiac disease, or history of treatment&#xD;
                  with cardiotoxic agents, should have a clinical risk assessment of cardiac&#xD;
                  function using the New York Heart Association Functional Classification.)&#xD;
&#xD;
               -  History of any condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study&#xD;
&#xD;
          -  Evidence of any of the following at registration:&#xD;
&#xD;
               -  Active uncontrolled infection requiring IV antibiotics&#xD;
&#xD;
               -  Baseline moderate and severe hepatic impairment (Child-Pugh class B &amp; C)&#xD;
&#xD;
               -  Inability to swallow oral pills&#xD;
&#xD;
               -  Any current condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study&#xD;
&#xD;
          -  Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset&#xD;
             of androgen ablation (both luteinizing hormone-releasing hormone [LHRH] agonist and&#xD;
             oral anti-androgen) is =&lt; 60 days prior to registration; Please note: baseline PSA and&#xD;
             testosterone must be obtained prior to the start of any ADT&#xD;
&#xD;
          -  PRIOR TO STEP 2 RANDOMIZATION:&#xD;
&#xD;
          -  Evidence of known gastrointestinal disorder affecting absorption of oral medications&#xD;
             at registration&#xD;
&#xD;
          -  For patients entering the Intensification Cohort ONLY: Any chronic medical condition&#xD;
             requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once&#xD;
             daily&#xD;
&#xD;
          -  For patients entering the Intensification Cohort ONLY: Presence of uncontrolled&#xD;
             hypertension (persistent systolic blood pressure [BP] &gt;= 160 mmHg or diastolic BP &gt;=&#xD;
             100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is&#xD;
             controlled to within these limits by anti-hypertensive treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul L Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin General Hospital</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayhealth Hospital Kent Campus</name>
      <address>
        <city>Dover</city>
        <state>Delaware</state>
        <zip>19901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants PA</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Lakewood Ranch</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Proton Therapy Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elmhurst Memorial Hospital</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hospital/Cancer Center</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology and Hematology Associates-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broadlawns Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan - Brighton Center for Specialty Care</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute-Downriver</name>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Macomb Hospital-Clinton Township</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center-Fairlane</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Farmington Hills</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Macomb</name>
      <address>
        <city>Macomb</city>
        <state>Michigan</state>
        <zip>48044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Madison Heights</name>
      <address>
        <city>Madison Heights</city>
        <state>Michigan</state>
        <zip>48071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center-Columbus</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Macomb Health Center - Shelby Township</name>
      <address>
        <city>Shelby</city>
        <state>Michigan</state>
        <zip>48315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA - Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Albert Lea</name>
      <address>
        <city>Albert Lea</city>
        <state>Minnesota</state>
        <zip>56007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Ellis Fischel</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Christian Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benefis Healthcare- Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital-Luckow Pavilion</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sands Cancer Center</name>
      <address>
        <city>Canandaigua</city>
        <state>New York</state>
        <zip>14424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center/Zimmer Cancer Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHRMC Radiation Oncology - 16th Street</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Mount Hood Medical Center</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital and Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Meridian Park Hospital</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Altoona</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Heritage Valley Health System Beaver</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlisle Regional Cancer Center</name>
      <address>
        <city>Carlisle</city>
        <state>Pennsylvania</state>
        <zip>17015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Concord Health Center</name>
      <address>
        <city>Chadds Ford</city>
        <state>Pennsylvania</state>
        <zip>19317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Erie</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center at UPMC Horizon</name>
      <address>
        <city>Farrell</city>
        <state>Pennsylvania</state>
        <zip>16121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers - Arnold Palmer Pavilion</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Cancer Center/Community Osteopathic Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Johnstown/John P. Murtha Regional Cancer Center</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center at UPMC McKeesport</name>
      <address>
        <city>McKeesport</city>
        <state>Pennsylvania</state>
        <zip>15132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle West Shore</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center - Monroeville</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Coraopolis/Heritage Valley Radiation Oncology</name>
      <address>
        <city>Moon</city>
        <state>Pennsylvania</state>
        <zip>15108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Saint Margaret</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Passavant Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Saint Clair Hospital Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center at UPMC Northwest</name>
      <address>
        <city>Seneca</city>
        <state>Pennsylvania</state>
        <zip>16346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Uniontown Hospital Radiation Oncology</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Washington Hospital Radiation Oncology</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Memorial</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Cancer Institute Medical Oncology and Day Treatment</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Salmon Creek Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheeling Hospital/Schiffler Cancer Center</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zablocki Veterans Administration Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
    <mesh_term>Buserelin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

